Endocrine Abstracts

Introduction: The antitumor activity of a novel cyclic amide, CLM94, with anti-VEGFR-2 and antiangiogenic activity, in primary anaplastic thyroid cancer (ATC) cells in vitro and in vivo, has been studied.Design and Methods: CLM94 was tested: i) in two human cell lines (HMVEC-d, dermal microvascular endothelial cells; 8305C, undifferentiated thyroid cancer) at 0.001–100 mcM; ii) in ATC cells at the concentrations of 10, 30, 50 mcM; iii)...